BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 22359288)

  • 1. DNA methylation in promoter region as biomarkers in prostate cancer.
    Yang M; Park JY
    Methods Mol Biol; 2012; 863():67-109. PubMed ID: 22359288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation in prostate cancer.
    Park JY
    Cancer Control; 2010 Oct; 17(4):245-55. PubMed ID: 20861812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation as a biomarker in prostate adenocarcinoma.
    Park JY
    Methods Mol Biol; 2015; 1238():607-25. PubMed ID: 25421683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.
    Sekita N; Suzuki H; Ichikawa T; Kito H; Akakura K; Igarashi T; Nakayama T; Watanabe M; Shiraishi T; Toyota M; Yoshie O; Ito H
    Jpn J Cancer Res; 2001 Sep; 92(9):947-51. PubMed ID: 11572762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
    Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
    Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
    Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
    Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling.
    Chung W; Kwabi-Addo B; Ittmann M; Jelinek J; Shen L; Yu Y; Issa JP
    PLoS One; 2008 Apr; 3(4):e2079. PubMed ID: 18446232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of the caveolin-1 gene promoter in prostate cancer.
    Cui J; Rohr LR; Swanson G; Speights VO; Maxwell T; Brothman AR
    Prostate; 2001 Feb; 46(3):249-56. PubMed ID: 11170154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation in prostate cancer.
    Li LC; Okino ST; Dahiya R
    Biochim Biophys Acta; 2004 Sep; 1704(2):87-102. PubMed ID: 15363862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genome-wide analysis of DNA methylation in prostate cancer using the technology of Infinium HumanMethylation450 BeadChip (HM450)].
    Babalyan KA; Sultanov R; Generozov EV; Zakharzhevskaya NB; Sharova EI; Peshkov MN; Vasilev AO; Govorov AV; Pushkar DY; Prilepskaya EA; Danilenko SA; Babikova EA; Larin AK; Govorun VM
    Vopr Onkol; 2016; 62(1):122-32. PubMed ID: 30444590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor.
    Park JY; Zheng W; Kim D; Cheng JQ; Kumar N; Ahmad N; Pow-Sang J
    Cancer Detect Prev; 2007; 31(5):359-65. PubMed ID: 18037591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
    Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.
    Stott-Miller M; Zhao S; Wright JL; Kolb S; Bibikova M; Klotzle B; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1331-9. PubMed ID: 24718283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.
    Basu S; Majumder S; Bhowal A; Ghosh A; Naskar S; Nandy S; Mukherjee S; Sinha RK; Basu K; Karmakar D; Banerjee S; Sengupta S
    PLoS One; 2015; 10(5):e0125560. PubMed ID: 25938433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer.
    Mazzu YZ; Yoshikawa Y; Nandakumar S; Chakraborty G; Armenia J; Jehane LE; Lee GM; Kantoff PW
    Mol Oncol; 2019 Sep; 13(9):1944-1958. PubMed ID: 31225930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetics of prostate cancer.
    Li LC
    Front Biosci; 2007 May; 12():3377-97. PubMed ID: 17485307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-κB/DNMT1 signaling pathway.
    Gao X; Mao YH; Xiao C; Li K; Liu W; Li LY; Pang J
    Prostate; 2018 Jun; 78(9):682-690. PubMed ID: 29601651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
    Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.